icon-folder.gif   Conference Reports for NATAP  
  50th ICAAC
Boston, MA
September 12-15, 2010
Back grey_arrow_rt.gif
Use of Genotypic and Maraviroc (MVC) Clinical Trial Data to Develop Statistical Models for Predicting Response in a Treatment-Naive (TN) Population
  Reported by Jules Levin
ICAAC Sept 14 2010 Boston
Pinaki Biswas1, Doug Chapman1, Xiaoyin Zhong3, Guinevere Q. Lee3, P. Richard Harrigan3, Jayvant Heera2, Hernan Valdez1 1Pfizer, New York, NY; 2Pfizer, New London, CT; 3BC Centre for Excellence in HIV/AIDS, Vancouver, Canada
"Of the 320 subjects with CD4+ count >50 and g2p FPR >5.75%, 67.2% responded"